nach oben

Diabetologia

Erschienen in:

01.05.2012 | Article

Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits

verfasst von: A. P. Gjesing, C. T. Ekstrøm, H. Eiberg, S. A. Urhammer, J. J. Holst, O. Pedersen, T. Hansen

Erschienen in: Diabetologia | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Heritability estimates have shown a varying degree of genetic contribution to traits related to type 2 diabetes. Therefore, the objective of this study was to investigate the familiality of fasting and stimulated measures of plasma glucose, serum insulin, serum C-peptide, plasma glucose-dependent insulinotropic polypeptide (GIP) and plasma glucagon-like peptide-1 (GLP-1) among non-diabetic relatives of Danish type 2 diabetic patients.

Methods

Sixty-one families comprising 193 non-diabetic offspring, 29 non-diabetic spouses, 72 non-diabetic relatives (parent, sibling, etc.) and two non-related relatives underwent a 4 h 75 g OGTT with measurements of plasma glucose, serum insulin, serum C-peptide, plasma GIP and plasma GLP-1 levels at 18 time points. Insulin secretion rates (ISR) and beta cell responses to glucose, GIP and GLP-1 were calculated. Familiality was estimated based on OGTT-derived measures.

Results

A high level of familiality was observed during the OGTT for plasma levels of GIP and GLP-1, with peak familiality values of 74 ± 16% and 65 ± 15%, respectively (h ² ± SE). Familiality values were lower for plasma glucose, serum insulin and serum C-peptide during the OGTT (range 8–48%, 14–44% and 15–61%, respectively). ISR presented the highest familiality value at fasting reaching 59 ± 16%. Beta cell responsiveness to glucose, GLP-1 and GIP also revealed a strong genetic influence, with peak familiality estimates of 62 ± 13%, 76 ± 15% and 70 ± 14%, respectively.

Conclusions/interpretation

Our results suggest that circulating levels of GIP and GLP-1 as well as beta cell response to these incretins are highly familial compared with more commonly investigated measures of glucose homeostasis such as fasting and stimulated plasma glucose, serum insulin and serum C-peptide.

Nur mit Berechtigung zugänglich

Dupuis J, Langenberg C, Prokopenko I et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105–116PubMedCrossRef

Visscher PM, Hill WG, Wray NR (2008) Heritability in the genomics era—concepts and misconceptions. Nat Rev Genet 9:255–266PubMedCrossRef

Simonis-Bik AM, Eekhoff EM, Diamant M et al (2008) The heritability of HbA1c and fasting blood glucose in different measurement settings. Twin Res Hum Genet 11:597–602PubMedCrossRef

Wang X, Ding X, Su S et al (2009) Heritability of insulin sensitivity and lipid profile depend on BMI: evidence for gene-obesity interaction. Diabetologia 52:2578–2584PubMedCrossRef

Bosy-Westphal A, Onur S, Geisler C et al (2007) Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. Int J Obes (Lond) 31:784–790

Henneman P, Aulchenko YS, Frants RR, van Dijk KW, Oostra BA, van Duijn CM (2008) Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen Family study. J Med Genet 45:572–577PubMedCrossRef

Sullivan CM, Futers TS, Barrett JH, Hudson BI, Freeman MS, Grant PJ (2005) RAGE polymorphisms and the heritability of insulin resistance: the Leeds family study. Diab Vasc Dis Res 2:42–44PubMedCrossRef

Freedman BI, Rich SS, Sale MM et al (2005) Genome-wide scans for heritability of fasting serum insulin and glucose concentrations in hypertensive families. Diabetologia 48:661–668PubMedCrossRef

Bellia A, Giardina E, Lauro D et al (2009) “The Linosa Study”: epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. Nutr Metab Cardiovasc Dis 19:455–461PubMedCrossRef

10.

Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H (1999) Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance – a population-based twin study. Diabetologia 42:139–145PubMedCrossRef

11.

Watanabe RM, Valle T, Hauser ER et al (1999) Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. Hum Hered 49:159–168PubMedCrossRef

12.

Lehtovirta M, Kaprio J, Forsblom C, Eriksson J, Tuomilehto J, Groop L (2000) Insulin sensitivity and insulin secretion in monozygotic and dizygotic twins. Diabetologia 43:285–293PubMedCrossRef

13.

Simonis-Bik AM, Boomsma DI, Dekker JM et al (2011) The heritability of beta cell function parameters in a mixed meal test design. Diabetologia 54:1043–1051PubMedCrossRef

14.

Schousboe K, Visscher PM, Henriksen JE, Hopper JL, Sorensen TI, Kyvik KO (2003) Twin study of genetic and environmental influences on glucose tolerance and indices of insulin sensitivity and secretion. Diabetologia 46:1276–1283PubMedCrossRef

15.

Elbein SC, Hasstedt SJ, Wegner K, Kahn SE (1999) Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 84:1398–1403PubMedCrossRef

16.

Rasmussen-Torvik LJ, Pankow JS, Jacobs DR et al (2007) Heritability and genetic correlations of insulin sensitivity measured by the euglycaemic clamp. Diabet Med 24:1286–1289PubMedCrossRef

17.

Bergman RN, Zaccaro DJ, Watanabe RM et al (2003) Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes 52:2168–2174PubMedCrossRef

18.

Freeman MS, Mansfield MW, Barrett JH, Grant PJ (2002) Heritability of features of the insulin resistance syndrome in a community-based study of healthy families. Diabet Med 19:994–999PubMedCrossRef

19.

Florez JC (2008) Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 51:1100–1110PubMedCrossRef

20.

So HC, Gui AH, Cherny SS, Sham PC (2011) Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol 35:310–317PubMedCrossRef

21.

Holst JJ, Gromada J, Nauck MA (1997) The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40:984–986PubMedCrossRef

22.

Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127–136PubMedCrossRef

23.

Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–52PubMedCrossRef

24.

Simonis-Bik AM, Eekhoff EM, de Moor MH et al (2009) Genetic influences on the insulin response of the beta cell to different secretagogues. Diabetologia 52:2570–2577PubMedCrossRef

25.

World Health Organization (1999) World Health Organization Diagnosis and Classification of Diabetes Mellitus: Report of a WHO Consultation, in Part 1. World Health Organization, Geneva

26.

Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME (1993) Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39:578–582PubMed

27.

Heding LG, Rasmussen SM (1975) Human C-peptide in normal and diabetic subjects. Diabetologia 11:201–206PubMedCrossRef

28.

Faber OK, Binder C, Markussen J et al (1978) Characterization of seven C-peptide antisera. Diabetes 27(Suppl 1):170–177PubMed

29.

Faber OK, Markussen J, Naithani VK, Binder C (1976) Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin. Hoppe Seylers Z Physiol Chem 357:751–757PubMedCrossRef

30.

Krarup T, Madsbad S, Moody AJ et al (1983) Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 56:1306–1312PubMedCrossRef

31.

Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539PubMedCrossRef

32.

Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458–E464PubMed

33.

Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA (1998) Measuring pre-hepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia 41:548–554PubMedCrossRef

34.

Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377PubMedCrossRef

35.

Hovorka R, Soons PA, Young MA (1996) ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50:253–264PubMedCrossRef

36.

Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386PubMedCrossRef

37.

Beaty TH, Fajans SS (1982) Estimating genetic and non-genetic components of variance for fasting glucose levels in pedigrees ascertained through non-insulin dependent diabetes. Ann Hum Genet 46:355–362PubMedCrossRef

38.

Boehnke M, Moll PP, Kottke BA, Weidman WH (1987) Partitioning the variability of fasting plasma glucose levels in pedigrees. Genetic and environmental factors. Am J Epidemiol 125:679–689PubMed

39.

Mills GW, Avery PJ, McCarthy MI et al (2004) Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. Diabetologia 47:732–738PubMedCrossRef

40.

Almgren P, Lehtovirta M, Isomaa B et al (2011) Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia 54(11):2811–2819PubMedCrossRef

Titel: Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits
verfasst von: A. P. Gjesing
C. T. Ekstrøm
H. Eiberg
S. A. Urhammer
J. J. Holst
O. Pedersen
T. Hansen
Publikationsdatum: 01.05.2012
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 5/2012
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-012-2484-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study, Norway

Hyperglycaemia normalises insulin action on glucose metabolism but not the impaired activation of AKT and glycogen synthase in the skeletal muscle of patients with type 2 diabetes

The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes

Serum 25-hydroxyvitamin D level during early pregnancy and type 1 diabetes risk in the offspring

Ciliary neurotrophic factor (CNTF) protects non-obese Swiss mice against type 2 diabetes by increasing beta cell mass and reducing insulin clearance